Micro Interventional Devices, Inc. Initiates “First-in-Man” Clinical Study of Permaseal™

STASIS Clinical Study Begins in Europe
Top-line Data Expected by Year End

NEWTOWN, Pa., Sept. 9, 2014 /PRNewswire/ — Micro Interventional Devices, Inc. (MID) reports the first successful clinical case using its Permaseal Cardiac Access and Closure technology.  This new technology simplifies minimally invasive aortic valve replacement procedures.  The patient is the first to be enrolled in the Secure Transapical Access and Closure Study (STASIS) being conducted in Europe.

This article appeared in the September 9, 2014 edition of Philadelphia Business Journal,  to continue reading click here:   http://www.bizjournals.com/philadelphia/prnewswire/press_releases/Georgia/2014/09/09/NE07701?ana=prnews

  • The Funding Process

    The Funding Process

    The Life Sciences Greenhouse of Central Pennsylvania provides investment funding up to $1 million in milestone-driven convertible…

    Read more
  • Our Resource Center


    It’s a familiar scenario. You hear about a discovery that could lead to the cure for this disease or that debilitating…

    Read more
  • The 'PA' in LSGPA


    The Life Sciences Greenhouse of Central Pennsylvania’s 42-county service area contains more than 60 institutions of higher …

    Read more